MED1

Summary

MED1 (mediator complex subunit 1, HGNC:9234) is a protein-coding gene on chromosome 17q12, encoding Mediator of RNA polymerase II transcription subunit 1 (Q15648). Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. It is a selective cancer dependency (DepMap: 64.3% of cell lines).

The activation of gene transcription is a multistep process that is triggered by factors that recognize transcriptional enhancer sites in DNA. These factors work with co-activators to direct transcriptional initiation by the RNA polymerase II apparatus. The protein encoded by this gene is a subunit of the CRSP (cofactor required for SP1 activation) complex, which, along with TFIID, is required for efficient activation by SP1. This protein is also a component of other multisubunit complexes e.g. thyroid hormone receptor-(TR-) associated proteins which interact with TR and facilitate TR function on DNA templates in conjunction with initiation factors and cofactors. It also regulates p53-dependent apoptosis and it is essential for adipogenesis. This protein is known to have the ability to self-oligomerize.

Source: NCBI Gene 5469 — RefSeq curated summary.

At a glance

• GWAS associations: 14
• Clinical variants (ClinVar): 179 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 64.3% of screened cell lines
• Transcription factor: yes — 17 downstream targets (CollecTRI)
• MANE Select transcript: NM_004774

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9234
Approved symbol	MED1
Name	mediator complex subunit 1
Location	17q12
Locus type	gene with protein product
Status	Approved
Aliases	PBP, TRAP220, RB18A, DRIP230, CRSP200, CRSP1
Ensembl gene	ENSG00000125686
Ensembl biotype	protein_coding
OMIM	604311
Entrez	5469

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000300651, ENST00000394287, ENST00000577831, ENST00000581334, ENST00000584308, ENST00000868127

RefSeq mRNA: 1 — MANE Select: NM_004774 NM_004774

CCDS: CCDS11336

Canonical transcript exons

ENST00000300651 — 17 exons

Exon	Start	End
ENSE00001111436	39440623	39440677
ENSE00001111460	39440386	39440518
ENSE00001303897	39404285	39410721
ENSE00001317542	39447798	39447904
ENSE00002724355	39451038	39451263
ENSE00003476594	39415026	39415131
ENSE00003495932	39423697	39423821
ENSE00003538922	39419717	39419918
ENSE00003569883	39424627	39424738
ENSE00003572992	39443550	39443628
ENSE00003586582	39415244	39415339
ENSE00003591801	39439165	39439193
ENSE00003596737	39427701	39427790
ENSE00003635188	39434249	39434320
ENSE00003656080	39431115	39431188
ENSE00003679502	39423327	39423445
ENSE00003679858	39431942	39432016

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 95.02.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.4403 / max 125.1591, expressed in 1778 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
165601	10.1581	1778
165600	0.2822	117

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	95.02	gold quality
nipple	UBERON:0002030	94.73	gold quality
visceral pleura	UBERON:0002401	93.30	gold quality
lower lobe of lung	UBERON:0008949	92.96	gold quality
mucosa of paranasal sinus	UBERON:0005030	92.66	gold quality
tongue squamous epithelium	UBERON:0006919	92.49	silver quality
superficial temporal artery	UBERON:0001614	92.41	gold quality
parietal pleura	UBERON:0002400	92.28	gold quality
trabecular bone tissue	UBERON:0002483	91.91	gold quality
penis	UBERON:0000989	91.59	gold quality
pleura	UBERON:0000977	91.38	gold quality
buccal mucosa cell	CL:0002336	91.25	gold quality
pylorus	UBERON:0001166	90.75	gold quality
cauda epididymis	UBERON:0004360	90.71	gold quality
caput epididymis	UBERON:0004358	90.64	gold quality
jejunal mucosa	UBERON:0000399	90.59	gold quality
mammalian vulva	UBERON:0000997	90.57	gold quality
oral cavity	UBERON:0000167	90.46	gold quality
mammary duct	UBERON:0001765	90.34	gold quality
renal medulla	UBERON:0000362	90.22	gold quality
corpus epididymis	UBERON:0004359	90.19	gold quality
urethra	UBERON:0000057	90.02	gold quality
epithelium of mammary gland	UBERON:0003244	89.97	gold quality
medial globus pallidus	UBERON:0002477	89.70	gold quality
esophagus squamous epithelium	UBERON:0006920	89.70	gold quality
pericardium	UBERON:0002407	89.56	gold quality
epithelium of nasopharynx	UBERON:0001951	89.48	gold quality
jejunum	UBERON:0002115	89.47	gold quality
nasopharynx	UBERON:0001728	89.46	gold quality
tibia	UBERON:0000979	89.06	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.78

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

17 targets.

Target	Regulation
ANKRD37
AR	Unknown
AURKA	Activation
CRABP2	Repression
FLG	Activation
GREB1
IRF8	Activation
IVL	Activation
KRT1	Activation
KRT10	Activation
LORICRIN	Activation
RARB	Repression
STC2
SULT2A1	Activation
THRA	Activation
UBE2C	Unknown
VDR	Unknown

Upstream regulators (CollecTRI, top): AR, EGF, ESR1, GATA6, NCOA1, NCOA3, NFKB, NR1H4, PAX1, RARA, RELA, STAT3, VDR, ZFPM1

miRNA regulators (miRDB)

191 targeting MED1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-96-5P	99.95	72.80	2140

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 64.3% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• regulates p53-dependent apoptosis (PMID:11840331)
• Interaction of PIMT with transcriptional coactivators CBP, p300, and PBP differential role in transcriptional regulation (PMID:11912212)
• MED1/TRAP220 is the nuclear receptor-interacting subunit of the Mediator complex and is required for PPARgamma-stimulated adipogenesis. (PMID:12037571)
• spermine significantly enhanced the interaction between HNF4alpha and full-length DRIP205 in an AF-2, NR-box-dependent manner. Spermine enhanced the interaction of DRIP205 with the VDR , but decreased the interaction of both HNF4alpha and VDR with GRIP1 (PMID:12089346)
• TFIID and human mediator coactivator (TRAP220) complexes assemble cooperatively on promoter DNA (PMID:12130544)
• there is a coregulatory role for subunits of this protein in androgen receptor-mediated gene expression (PMID:12218053)
• examination of regulation by cellular signaling pathways (PMID:12356758)
• extended LXXLL motif sequence determines the nuclear receptor binding specificity (PMID:12556447)
• DRIP205 has a role as a coactivator of FXR (PMID:15187081)
• DRIP205 coactivation of estrogen receptor alpha (ERalpha) involves multiple domains of both proteins (PMID:15471764)
• RB18A plays a central role to control p53wt and p53mut protein content and functions in cells through a loop of regulation, which involves MDM2 (PMID:15848166)
• MED1 exists predominantly in a TRAP/Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. (PMID:15989967)
• MED14 and MED1 are used by glucocorticoid receptor in a gene-specific manner, providing a mechanism for promoter selectivity by glucocorticoid receptor (PMID:16239257)
• ERK-mediated phosphorylation is a regulatory mechanism that controls TRAP220/Med1 expression levels and modulates its functional activity. (PMID:16314496)
• TRAP220/MED1 plays a novel coregulatory role in facilitating the recruitment of TRAP/Mediator to specific target genes involved in growth and cell cycle progression via GABP (PMID:16574658)
• Med1 depleted cells exhibited an exacerbated response to retinoids, both in terms transcriptional responses and of cellular differentiation. (PMID:16723356)
• Expression of TRAP220 mRNA and protein was shown to be decreased significantly in the temporal cortex of patients with epilepsy. (PMID:16934225)
• Both DRIP205 and SRC-3 are required for the keratinocyte differentiation (PMID:17223341)
• Recruitment of CBP and TRAP220 was diminished by the overexpression of a MED25 NR box deletion mutant, and by treatment with MED25 siRNA (PMID:17641689)
• phosphorylation of RXRalpha at serine 260 impaired the recruitment of DRIP205 and other coactivators to the VDR.RXRalpha complex (PMID:18003614)
• ERK-regulated site in Med1 protein is also essential for up-regulating interferon-induced transcription although not critical for binding to C/EBP-beta (PMID:18339625)
• ERK phosphorylation of MED1 is a regulatory mechanism that promotes MED1 association with Mediator and, as such, may facilitate a novel feed-forward action of nuclear hormones (PMID:18391015)
• Decreased MED1 transcript levels are observed in matched normal mucosa when compared with colorectal and ovarian cancers. (PMID:19127118)
• a decrease of RB18A/MED1 expression in human melanoma cells increases their tumorigenic phenotype. (PMID:19243021)
• MED1 and GATA-6 are key regulators of SULT2A1 expression, and they play important roles in adrenal androgen production. (PMID:19497978)
• Loss of Med1 expression directly correlates with a loss of dapk1 expression in a number of human lung cancers and cancer cell lines. (PMID:19521987)
• Results show that the cells of this aggressive form of breast cancer are genetically preprogrammed to depend on NR1D1 and PBP for the energy production necessary for survival. (PMID:20160030)
• analysis of molecular mechanism of binding TRAP220 coactivator to Retinoid X Receptor alpha, activated by 9-cis retinoic acid (PMID:20398753)
• Vitamin D receptor rs2228570 polymorphism is associated with invasive ovarian carcinoma. (PMID:20473893)
• The core subunit MED1 facilitates VDR activity and regulating keratinocyte proliferation and differentiation (PMID:20520624)
• analysis of mediator in three different structural states: bound to the activator SREBP-1a, VP16, or an activator-free state (PMID:20534441)
• Studies indicate that the activation domain of p53 (p53AD) binds directly to the MED17 subunit of Mediator, whereas the p53 C-terminal domain (p53CTD) binds the MED1 subunit. (PMID:21326907)
• establish ARGLU1 as a new MED1-interacting protein required for estrogen-dependent gene transcription and breast cancer cell growth. (PMID:21454576)
• MED1 phosphorylation leads to ubiquitin-conjugating enzyme E2C (UBE2C) locus looping, UBE2C gene expression and cell growth in castration-resistant prostate cancer. (PMID:21556051)
• Regulation of androgen receptor-dependent transcription by coactivator MED1 is mediated through a newly discovered noncanonical binding motif. (PMID:22102282)
• functional communications between the MED1 subunit and the MED24-containing submodule that mediate estrogen receptor functions and growth of both normal mammary epithelial cells and breast carcinoma cells. (PMID:22331469)
• Med1 (also known as PBP/RB18A/TRAP220/DRIP205) is a component of the human TRAP/Mediator complex that plays an important role in the transcriptional control of various genes (PMID:22342682)
• These results suggest that Mediator structural shifts induced by activator binding help stably orient pol II prior to transcription initiation within the human mediator-RNA polymerase II-TFIIF assembly. (PMID:22343046)
• MiR-205 is an epigenetically regulated tumor suppressor that targets MED1. (PMID:22869146)
• MED1 is recruited to the HER2 gene and required for its expression. (PMID:22964581)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	med1	ENSDARG00000075340
mus_musculus	Med1	ENSMUSG00000018160
rattus_norvegicus	Med1	ENSRNOG00000005606
drosophila_melanogaster	MED1	FBGN0037109

Protein

Protein identifiers

Mediator of RNA polymerase II transcription subunit 1 — Q15648 (reviewed: Q15648)

Alternative names: Activator-recruited cofactor 205 kDa component, Mediator complex subunit 1, Peroxisome proliferator-activated receptor-binding protein, Thyroid hormone receptor-associated protein complex 220 kDa component, Thyroid receptor-interacting protein 2, Vitamin D receptor-interacting protein complex component DRIP205, p53 regulatory protein RB18A

All UniProt accessions (3): Q15648, J3KSD7, J3QKZ7

UniProt curated annotations — full annotation on UniProt →

Function. Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. Acts as a coactivator for GATA1-mediated transcriptional activation during erythroid differentiation of K562 erythroleukemia cells.

Subunit / interactions. Component of the Mediator complex, which is composed of MED1, MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L, MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23, MED24, MED25, MED26, MED27, MED29, MED30, MED31, CCNC, CDK8 and CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8 subunits form a distinct module termed the CDK8 module. Mediator containing the CDK8 module is less active than Mediator lacking this module in supporting transcriptional activation. Individual preparations of the Mediator complex lacking one or more distinct subunits have been variously termed ARC, CRSP, DRIP, PC2, SMCC and TRAP. This subunit specifically interacts with a number of nuclear receptors in a ligand-dependent fashion including AR, ESR1, ESR2, PPARA, PPARG, RORA, RXRA, RXRG, THRA, THRB and VDR. Interacts with CTNNB1, GABPA, GLI3, PPARGC1A and TP53. Interacts with YWHAH. Interacts with CLOCK; this interaction requires the presence of THRAP3. Interacts with GATA1 and CCAR1. Interacts with NR4A3. Interacts (via IBM motif) with PSIP1 (via IBD domain); phosphorylation increases its affinity for PSIP1. Interacts with USP22. Interacts with PRDM16; promoting recruitment of the Mediator complex to chromatin and activation of genes that are highly expressed in brown adipocytes.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitously expressed.

Post-translational modifications. Phosphorylated by MAPK1 or MAPK3 during G2/M phase which may enhance protein stability and promote entry into the nucleolus. Phosphorylation increases its interaction with PSIP1.

Similarity. Belongs to the Mediator complex subunit 1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q15648-1	1	yes
Q15648-3	2

RefSeq proteins (1): NP_004765* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019680	Mediator_Med1	Domain
IPR051999	Mediator_complex_subunit_1	Family

Pfam: PF10744

UniProt features (127 total): modified residue 26, helix 18, compositionally biased region 18, strand 17, region of interest 14, mutagenesis site 14, sequence conflict 12, short sequence motif 3, splice variant 2, sequence variant 2, chain 1

Structure

Experimental structures (PDB)

84 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
9IWM	X-RAY DIFFRACTION	1.39
9VOG	X-RAY DIFFRACTION	1.43
9M1D	X-RAY DIFFRACTION	1.44
9M1C	X-RAY DIFFRACTION	1.67
9M13	X-RAY DIFFRACTION	1.68
2O4J	X-RAY DIFFRACTION	1.74
9VOL	X-RAY DIFFRACTION	1.75
9M1B	X-RAY DIFFRACTION	1.77
9M1A	X-RAY DIFFRACTION	1.78
3W0H	X-RAY DIFFRACTION	1.8
6K5O	X-RAY DIFFRACTION	1.8
3AUN	X-RAY DIFFRACTION	1.81
9M17	X-RAY DIFFRACTION	1.81
3W0J	X-RAY DIFFRACTION	1.84
9M12	X-RAY DIFFRACTION	1.86
5B41	X-RAY DIFFRACTION	1.89
1RKG	X-RAY DIFFRACTION	1.9
3VRV	X-RAY DIFFRACTION	1.9
3W0I	X-RAY DIFFRACTION	1.9
3W5P	X-RAY DIFFRACTION	1.9
3W5Q	X-RAY DIFFRACTION	1.9
3WT5	X-RAY DIFFRACTION	1.9
6D94	X-RAY DIFFRACTION	1.9
7C7W	X-RAY DIFFRACTION	1.9
3VJS	X-RAY DIFFRACTION	1.93
9VOI	X-RAY DIFFRACTION	1.93
9VOJ	X-RAY DIFFRACTION	1.93
3W0G	X-RAY DIFFRACTION	1.94
7VQP	X-RAY DIFFRACTION	1.94
5XPN	X-RAY DIFFRACTION	1.96

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15648-F1	50.91	0.10

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (26): 588, 664, 795, 805, 887, 953, 1032, 1051, 1057, 1156, 1177, 1207, 1215, 1223, 1302, 1347, 1403, 1433, 1440, 1457 …

Mutagenesis-validated functional residues (14):

Position	Phenotype
599–612	enhances interaction with esr1.
600–612	enhances interaction with esr1.
604	impairs interaction with esr2; when associated with a-607; a-645 and a-648.
607–608	impairs interaction with esr1, pparg, rxra and thrb. impairs interaction with thra; when associated with 648-a-a-649.
607	impairs interaction with esr2; when associated with a-604; a-645 and a-648.
639–653	enhances interaction with esr1.
645	impairs interaction with esr2; when associated with a-604; a-607 and a-648.
648–649	impairs interaction with esr1, pparg, thrb and vdr. impairs interaction with thra; when associated with 607-a-a-608.
648	impairs interaction with esr2; when associated with a-604; a-607 and a-645.
886	increased interaction with psip1; when associated with d-887 or d-887 and d-889.
887	phosphomimetic mutant. increased interaction with psip1; when associated with d-886 or d-886 and d-889.
889	increased interaction with psip1; when associated with d-886 and d-887.
1032	enhances protein stability; when associated with a-1457.
1457	enhances protein stability; when associated with a-1032.

Function

Pathways and Gene Ontology

Reactome pathways

41 pathways

ID	Pathway
R-HSA-1368108	BMAL1:CLOCK,NPAS2 activates circadian expression
R-HSA-1989781	PPARA activates gene expression
R-HSA-212436	Generic Transcription Pathway
R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis
R-HSA-2426168	Activation of gene expression by SREBF (SREBP)
R-HSA-381340	Transcriptional regulation of white adipocyte differentiation
R-HSA-383280	Nuclear Receptor transcription pathway
R-HSA-400206	Regulation of lipid metabolism by PPARalpha
R-HSA-9018519	Estrogen-dependent gene expression
R-HSA-9707564	Cytoprotection by HMOX1
R-HSA-9707616	Heme signaling
R-HSA-9833110	RSV-host interactions
R-HSA-9841922	MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
R-HSA-9931509	Expression of BMAL (ARNTL), CLOCK, and NPAS2
R-HSA-9933387	RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
R-HSA-1266738	Developmental Biology
R-HSA-1368082
R-HSA-1430728	Metabolism
R-HSA-1592230	Mitochondrial biogenesis
R-HSA-162582	Signal Transduction
R-HSA-1643685	Disease
R-HSA-1655829	Regulation of cholesterol biosynthesis by SREBP (SREBF)
R-HSA-1852241	Organelle biogenesis and maintenance
R-HSA-212165	Epigenetic regulation of gene expression
R-HSA-2262752	Cellular responses to stress
R-HSA-400253
R-HSA-556833	Metabolism of lipids
R-HSA-5663205	Infectious disease
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 482 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_CARDIAC_CHAMBER_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_EPITHELIAL_CELL_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_CELL_PROLIFERATION, REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_REGULATION_OF_HEPATOCYTE_PROLIFERATION, GOBP_PHENOL_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOBP_HEPATICOBILIARY_SYSTEM_DEVELOPMENT, GOBP_EMBRYONIC_HEMOPOIESIS, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, AAGCAAT_MIR137, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_MAMMARY_GLAND_MORPHOGENESIS, GOBP_NEGATIVE_REGULATION_OF_NEURON_DIFFERENTIATION

GO Biological Process (62): negative regulation of transcription by RNA polymerase II (GO:0000122), cell morphogenesis (GO:0000902), angiogenesis (GO:0001525), liver development (GO:0001889), embryonic placenta development (GO:0001892), lens development in camera-type eye (GO:0002088), thyroid hormone receptor signaling pathway (GO:0002154), ventricular trabecula myocardium morphogenesis (GO:0003222), retinal pigment epithelium development (GO:0003406), regulation of transcription by RNA polymerase II (GO:0006357), thyroid hormone generation (GO:0006590), protein import into nucleus (GO:0006606), androgen biosynthetic process (GO:0006702), brain development (GO:0007420), lactation (GO:0007595), positive regulation of gene expression (GO:0010628), negative regulation of keratinocyte proliferation (GO:0010839), protein ubiquitination (GO:0016567), keratinocyte differentiation (GO:0030216), monocyte differentiation (GO:0030224), nuclear receptor-mediated steroid hormone signaling pathway (GO:0030518), animal organ regeneration (GO:0031100), positive regulation of transcription elongation by RNA polymerase II (GO:0032968), positive regulation of intracellular estrogen receptor signaling pathway (GO:0033148), embryonic heart tube development (GO:0035050), embryonic hindlimb morphogenesis (GO:0035116), embryonic hemopoiesis (GO:0035162), peroxisome proliferator activated receptor signaling pathway (GO:0035357), cellular response to hepatocyte growth factor stimulus (GO:0035729), megakaryocyte development (GO:0035855), mRNA transcription by RNA polymerase II (GO:0042789), negative regulation of apoptotic process (GO:0043066), G0 to G1 transition (GO:0045023), fat cell differentiation (GO:0045444), positive regulation of keratinocyte differentiation (GO:0045618), positive regulation of erythrocyte differentiation (GO:0045648), negative regulation of neuron differentiation (GO:0045665), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), erythrocyte development (GO:0048821)

GO Molecular Function (23): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), transcription coactivator binding (GO:0001223), chromatin binding (GO:0003682), transcription coregulator activity (GO:0003712), transcription coactivator activity (GO:0003713), transcription corepressor activity (GO:0003714), nuclear receptor binding (GO:0016922), nuclear estrogen receptor binding (GO:0030331), chromatin DNA binding (GO:0031490), histone acetyltransferase binding (GO:0035035), nuclear vitamin D receptor binding (GO:0042809), nuclear retinoic acid receptor binding (GO:0042974), peroxisome proliferator activated receptor binding (GO:0042975), protein-containing complex binding (GO:0044877), nuclear thyroid hormone receptor binding (GO:0046966), LBD domain binding (GO:0050693), ubiquitin protein ligase activity (GO:0061630), general transcription initiation factor binding (GO:0140296), DNA-binding transcription factor binding (GO:0140297), promoter-specific chromatin binding (GO:1990841), DNA binding (GO:0003677), protein binding (GO:0005515), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629)

GO Cellular Component (9): ubiquitin ligase complex (GO:0000151), chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), membrane (GO:0016020), mediator complex (GO:0016592), protein-DNA complex (GO:0032993), core mediator complex (GO:0070847)

Reactome top-level categories

Rollup of top-14 pathways:

Category	Pathways
Circadian clock	3
Regulation of lipid metabolism by PPARalpha	1
RNA Polymerase II Transcription	1
Mitochondrial biogenesis	1
Regulation of cholesterol biosynthesis by SREBP (SREBF)	1
Adipogenesis	1
Generic Transcription Pathway	1
Metabolism of lipids	1
ESR-mediated signaling	1
Cellular response to chemical stress	1
Cellular responses to stress	1
Respiratory Syncytial Virus Infection Pathway	1
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	1
Organelle biogenesis and maintenance	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nuclear receptor binding	4
cellular anatomical structure	3
transcription by RNA polymerase II	2
negative regulation of DNA-templated transcription	2
binding	2
transcription coregulator activity	2
chromatin binding	2
transcription factor binding	2
nuclear lumen	2
regulation of transcription by RNA polymerase II	1
anatomical structure morphogenesis	1
blood vessel morphogenesis	1
anatomical structure formation involved in morphogenesis	1
gland development	1
hepaticobiliary system development	1
in utero embryonic development	1
placenta development	1
embryonic organ development	1
camera-type eye development	1
anatomical structure development	1
hormone-mediated signaling pathway	1
nuclear receptor-mediated signaling pathway	1
ventricular cardiac muscle tissue morphogenesis	1
heart trabecula morphogenesis	1
retina development in camera-type eye	1
epithelium development	1
regulation of DNA-templated transcription	1
thyroid hormone metabolic process	1
intracellular protein transport	1
protein localization to nucleus	1
import into nucleus	1
establishment of protein localization to organelle	1
androgen metabolic process	1
hormone biosynthetic process	1
steroid hormone biosynthetic process	1
central nervous system development	1
animal organ development	1
head development	1
body fluid secretion	1
mammary gland development	1

Protein interactions and networks

STRING

4954 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MED1	MED24	O75448	972
MED1	PPARG	P37231	961
MED1	MED14	O60244	961
MED1	ESR1	P03372	934
MED1	MED17	Q9NVC6	875
MED1	MED23	Q9ULK4	850
MED1	NCOA1	Q15788	827
MED1	MED12	Q93074	791
MED1	GATA1	P15976	786
MED1	MED26	O95402	781
MED1	GTF2A1	P52655	781
MED1	CCNC	P24863	771
MED1	TP53	P04637	759
MED1	MED4	Q9NPJ6	741
MED1	NCOA6	Q14686	733

IntAct

207 interactions, top by confidence:

A	B	Type	Score
CDK8	MED1	psi-mi:“MI:0914”(association)	0.920
CDK8	MED1	psi-mi:“MI:0915”(physical association)	0.920
MED10	MED19	psi-mi:“MI:0914”(association)	0.910
MED10	MED19	psi-mi:“MI:0915”(physical association)	0.910
CDK8	MED14	psi-mi:“MI:0914”(association)	0.900
MED4	MED19	psi-mi:“MI:2364”(proximity)	0.900
MED4	MED19	psi-mi:“MI:0914”(association)	0.900
MED29	MED19	psi-mi:“MI:0914”(association)	0.890
MED21	MED19	psi-mi:“MI:0914”(association)	0.880
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
CDK8	MED19	psi-mi:“MI:0914”(association)	0.850

BioGRID (598): MED1 (Protein-peptide), MED1 (Co-crystal Structure), MED1 (Reconstituted Complex), PPARG (Reconstituted Complex), MED1 (Two-hybrid), MED1 (Protein-peptide), MED1 (Affinity Capture-MS), MED1 (Affinity Capture-MS), MED1 (Affinity Capture-MS), MED1 (Affinity Capture-MS), MED1 (Affinity Capture-MS), MED1 (Affinity Capture-MS), MED1 (Affinity Capture-MS), MED1 (Affinity Capture-MS), MED1 (Co-fractionation)

ESM2 similar proteins: A0JP85, A1A5H6, A2AGH6, A2RRV3, A5GFY4, A5YKK6, B1AY13, E9Q8I9, O55007, O75448, O94915, O95155, Q0KK59, Q15648, Q24134, Q2PW47, Q2QCI8, Q4V8B3, Q5F3M0, Q5RCU2, Q5RES4, Q5RFA0, Q5TBA9, Q642P2, Q6GLR7, Q6GYP7, Q6GYQ0, Q6P4S8, Q6PI53, Q6ZQ08, Q7YQK8, Q80TJ1, Q80X82, Q80YV3, Q86YW9, Q8BL99, Q8BQM9, Q8IXH7, Q8N201, Q922L6

Diamond homologs: A1L0Z0, Q15648, Q172G3, Q5RES4, Q6INP8, Q925J9, Q9VP05

SIGNOR signaling

7 interactions.

A	Effect	B	Mechanism
MAPK1	up-regulates	MED1	phosphorylation
MED1	“form complex”	“Core mediator complex”	binding
Gbeta	up-regulates	MED1	phosphorylation
ERK1/2	up-regulates	MED1	phosphorylation
MAPK3	up-regulates	MED1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 105 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Respiratory Syncytial Virus Infection Pathway	28	68.1×	9e-45
Adipogenesis	30	57.9×	2e-45
FGFR2 mutant receptor activation	6	56.4×	1e-08
RSV-host interactions	28	54.1×	3e-41
Regulation of lipid metabolism by PPARalpha	31	54.0×	1e-45
Transcriptional regulation of white adipocyte differentiation	33	52.9×	4e-48
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	17	45.2×	5e-23
Signaling by FGFR2 IIIa TM	6	44.5×	3e-08

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of transcription elongation by RNA polymerase II	25	77.6×	4e-40
RNA polymerase II preinitiation complex assembly	26	72.9×	1e-40
positive regulation of transcription initiation by RNA polymerase II	26	72.9×	1e-40
intracellular receptor signaling pathway	7	71.5×	3e-10
cellular response to estrogen stimulus	5	48.3×	3e-06
retinoic acid receptor signaling pathway	6	40.1×	5e-07
transcription initiation at RNA polymerase II promoter	10	38.6×	9e-12
mRNA transcription by RNA polymerase II	10	34.1×	3e-11

Disease & clinical

Clinical variants and AI predictions

ClinVar

179 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	156
Likely benign	9
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

10459 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:39408046:A:C	I1392S	1.000
17:39408046:A:G	I1392T	1.000
17:39408292:A:G	L1310P	1.000
17:39408304:A:T	V1306D	1.000
17:39408313:A:C	L1303W	1.000
17:39408313:A:G	L1303S	1.000
17:39410278:A:G	L648P	1.000
17:39410287:A:G	L645P	1.000
17:39410287:A:T	L645H	1.000
17:39410410:A:G	L604P	1.000
17:39410410:A:T	L604H	1.000
17:39410677:G:T	A515D	1.000
17:39410678:C:G	A515P	1.000
17:39410686:C:G	R512P	1.000
17:39410689:A:T	I511N	1.000
17:39410692:G:T	A510D	1.000
17:39410693:C:G	A510P	1.000
17:39415046:G:C	F493L	1.000
17:39415046:G:T	F493L	1.000
17:39415048:A:G	F493L	1.000
17:39415058:G:C	C489W	1.000
17:39415059:C:T	C489Y	1.000
17:39415060:A:G	C489R	1.000
17:39415269:G:C	H456Q	1.000
17:39415269:G:T	H456Q	1.000
17:39415270:T:C	H456R	1.000
17:39415275:A:C	F454L	1.000
17:39415275:A:T	F454L	1.000
17:39415276:A:G	F454S	1.000
17:39415277:A:G	F454L	1.000

dbSNP variants (sampled 300 via entrez): RS1000135705 (17:39430655 T>C), RS1000226222 (17:39429414 G>C), RS1000361938 (17:39416924 C>A,T), RS1000434360 (17:39419465 T>A), RS1000504304 (17:39443062 C>A,T), RS1000516286 (17:39435493 A>G,T), RS1000534723 (17:39447155 C>T), RS1000594305 (17:39438470 G>C), RS1000622001 (17:39442382 G>C), RS1000644325 (17:39412514 A>C), RS1000726222 (17:39429093 G>A,C), RS1000736673 (17:39435780 C>T), RS1000745865 (17:39432184 A>G), RS1000912188 (17:39411356 C>G,T), RS1000981178 (17:39406078 C>G,T)

Disease associations

OMIM: gene MIM:604311 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), intellectual disability (MONDO:0001071)

Orphanet (2): Familial prostate cancer (Orphanet:1331), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST000624_15	Ulcerative colitis	3.000000e-08
GCST002318_79	Rheumatoid arthritis	2.000000e-08
GCST002463_23	Systemic lupus erythematosus	7.000000e-07
GCST005984_41	Glomerular filtration rate	4.000000e-14
GCST005985_16	Creatinine levels	9.000000e-13
GCST006291_14	Spherical equivalent or myopia (age of diagnosis)	3.000000e-08
GCST006483_60	Lung function (FVC)	1.000000e-08
GCST006959_173	Rheumatoid arthritis	1.000000e-08
GCST007344_86	Estimated glomerular filtration rate	2.000000e-24
GCST008916_10	Asthma	5.000000e-09
GCST008916_21	Asthma	2.000000e-62
GCST008916_45	Asthma	3.000000e-10
GCST008916_86	Asthma	2.000000e-14
GCST010002_123	Refractive error	1.000000e-24

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004847	age at onset
EFO:0004312	vital capacity

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724624 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.68	Kd	207	nM	MOLIBRESIB
6.60	IC50	250	nM	MOLIBRESIB

PubChem BioAssay actives

2 with measured affinity, of 11 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179214: Binding affinity against MED1 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.2070	uM

CTD chemical–gene interactions

68 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases reaction, affects binding, increases reaction, increases expression	4
Rifampin	affects binding, increases activity, increases reaction, decreases expression	3
pirinixic acid	affects binding, increases activity, increases expression, increases reaction	2
bisphenol A	affects binding, affects folding, decreases reaction, increases activity, increases reaction	2
INT 131	affects binding, decreases reaction	2
bisphenol S	affects binding, affects folding, decreases reaction, increases reaction	2
bisphenol AF	affects binding, affects folding, decreases reaction	2
Rosiglitazone	affects binding, decreases reaction	2
Tretinoin	increases reaction, decreases expression, affects binding	2
FR900359	affects phosphorylation	1
butamben	affects binding, increases reaction	1
triphenyl phosphate	affects expression	1
alfacalcidol	affects binding, increases reaction	1
arsenite	increases expression, decreases reaction	1
mono-(2-ethylhexyl)phthalate	affects binding, increases reaction	1
sodium arsenite	decreases expression	1
potassium bromate	decreases phosphorylation	1
coumarin	increases phosphorylation	1
phenothiazine	affects binding, decreases reaction	1
phthalic acid	affects binding, increases reaction	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
sulconazole	affects binding, increases reaction	1
dicyclohexyl phthalate	affects binding, increases reaction	1
26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3	affects binding, increases reaction	1
testosterone-3-carboxymethyloxime-bovine serum albumin conjugate	affects expression	1
clemizole	affects binding, increases reaction	1
cylindrospermopsin	increases expression	1
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	decreases phosphorylation	1
1,25-dihydroxyvitamin D	affects binding, affects cotreatment, increases reaction	1
dihydroxy-vitamin D3	affects binding, increases reaction	1

ChEMBL screening assays

11 unique, capped per target: 11 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5675845	Binding	Inhibition of MED1 in human TPC1 cells assessed as reduction of MED11 binding to all active RUNX2 regulatory elements (ENH11,ENH13) at 1 uM by ChIP analysis	RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN. — Nucleic Acids Res

Cellosaurus cell lines

5 cell lines: 5 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_KY79	PathHunter CHO-K1 PPARalpha Protein Interaction	Spontaneously immortalized cell line	Female
CVCL_KY80	PathHunter CHO-K1 PPARdelta Protein Interaction	Spontaneously immortalized cell line	Female
CVCL_KY81	PathHunter CHO-K1 PPARgamma Protein Interaction	Spontaneously immortalized cell line	Female
CVCL_KY92	PathHunter CHO-K1 RARalpha Protein Interaction	Spontaneously immortalized cell line	Female
CVCL_KZ21	PathHunter CHO-K1 THRbeta Protein Interaction	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer